JNGLX — Janus Henderson Global Life Sciences Fund
Data updated: 2026-05-29
JNGLX — Janus Henderson Global Life Sciences Fund data: holdings, portfolio allocation, expenses, performance, cashflows, risk and SEC filings. United States Health Care Equity · $5.20B AUM · 0.81% expense ratio · 19.0% 1-yr return. From SEC regulatory filings.
JNGLX Fund Overview
JNGLX — Janus Henderson Global Life Sciences Fund is a US mutual fund managed by Janus Investment Fund, categorised as United States Health Care Equity. ABC INVEST provides holdings, performance, costs, cashflows, risk data, prospectus documents and SEC filings, sourced from SEC filings.
- Type: US mutual fund
- Manager: Janus Investment Fund
- Category: United States Health Care Equity
- Assets under management: $5.20B
- 1-year return: 19.0%
- Ticker: JNGLX
- SEC CIK: 0000277751
- SEC series ID: S000010494
- Share class ID: C000083538
JNGLX Holdings
Top 10 holdings of Janus Henderson Global Life Sciences Fund by percentage of net assets, from the fund's latest SEC N-PORT filing.
| Holding | % of net assets |
|---|---|
| Eli Lilly & Co. | 8.84% |
| Johnson & Johnson | 7.29% |
| AstraZeneca PLC | 4.59% |
| AbbVie Inc. | 4.05% |
| UnitedHealth Group Inc. | 3.13% |
| Novartis AG | 2.86% |
| Thermo Fisher Scientific Inc | 2.51% |
| Praxis Precision Medicines Inc | 2.45% |
| Argenx SE | 2.40% |
| Abbott Laboratories | 2.40% |
JNGLX Portfolio Allocation
Asset-class allocation of Janus Henderson Global Life Sciences Fund by percentage of net assets, from the latest SEC N-PORT filing.
| Asset class | Allocation |
|---|---|
| Equity | 91.2% |
| Other | 8.7% |
JNGLX Performance
Total returns for JNGLX (as of 2026-08-01), from SEC filings.
| Period | Total return |
|---|---|
| YTD | -3.7% |
| 1 year | 19.0% |
| 3 years (annualised) | 10.7% |
| 5 years (annualised) | 7.4% |
JNGLX Risk Information
Risk metrics for JNGLX, derived from monthly returns in SEC filings.
- 1-year volatility (annualised): 16.9%
JNGLX Costs and Fees
JNGLX costs about $81 per $10,000 invested per year in fund expenses.
- Net expense ratio: 0.81%
- Gross expense ratio: 0.81%
- Portfolio turnover: 30%
- Brokerage commissions: 2.61 bps of average net assets (SEC N-CEN)
JNGLX Cashflows
Over the 12 months to 2026-03, Janus Henderson Global Life Sciences Fund had net outflows of $101.65M, from monthly SEC N-PORT filings.
| Month | Net flow |
|---|---|
| 2026-03 | $12.46M |
| 2026-02 | $33.34M |
| 2026-01 | −$6.42M |
| 2025-12 | $208.51M |
| 2025-11 | −$15.07M |
| 2025-10 | −$20.82M |
JNGLX Debt Constituents
No individual debt constituents are reported in Janus Henderson Global Life Sciences Fund's latest SEC N-PORT filing.
JNGLX Prospectus and SEC Filings
Official Janus Henderson Global Life Sciences Fund filings on SEC EDGAR — prospectus, portfolio holdings and annual reports.
Related Funds
Other United States Health Care Equity funds tracked on ABC INVEST:
Data Sources
ABC INVEST compiles this page from public filings made to the U.S. Securities and Exchange Commission (SEC) through EDGAR: portfolio holdings and monthly cashflows from Form N-PORT, expenses and returns from fund prospectuses (Form 485BPOS) and the SEC DERA Risk/Return Summary data sets, annual data from Form N-CEN, and shareholder reports from Form N-CSR.